Skip to main content

News and blog posts

18
Jun 2018

Effectiveness of shunt treatment for persons with idiopathic normal pressure hydrocephalus report was published by the Norwegian Institute of Public Health at the end of May of 2018

On the 30th of May of 2018, Norwegian Institute of Public Health (NIPH) has published a report regarding effectiveness of shunt treatment for persons with idiopathic normal pressure hydrocephalus, which was earlier commissioned to NIPH by My treatment choices platform with the purpose to find and summarize key findings from systematic reviews about the effects of shunts in the treatment of idiopathic normal pressure hydrocephalus.
13
Jun 2018

Updated list of laboratory tests in Switzerland

The list of the laboratory tests is based on the Services Order (Ordinanza sulle Prestazioni, OPre) of the September 29th, 1995; the latest update is in force since January 1st, 2018. The list contains the services whose costs are covered by the obligatory healthcare insurance (assicurazione obbligatoria delle cure medico-sanitarie, AOMS). With the latest update, there are 1931 tests on this list. See the list of the January 2018 modifications in Italian here. See the full list of current laboratory tests in Excel format (in French, German and Italian) here. Subscribe to our newsletter delivered every second week not to miss important reimbursement information.
07
Jun 2018

Two additional indications for application of positron emission tomography (PET)/computed tomography (CT) in malignant lymphomas was approved by the Federal Joint Committee (G-BA) in May of 2018

In May of 2018, the Federal Joint Committee (G-BA) approved two additional indications for application of PET/CT for management of malignant lymphomas for coverage within statutory health insurance. As the procedures were included into Directive for methods and examinations and Directive methods of the contract medical care, they are now reimbursed in both hospital and out-patient settings.
05
Jun 2018

Several breathing chambers were included in the list of pharmaceutical benefits by Dental and Pharmaceutical Benefit Agency

On the 14th of May of 2018, Dental and Pharmaceutical Benefit Agency (Tandvårds- och läkemedelsförmånsverket, TLV) has published a decision regarding inclusion of number of consumable medical devices for the treatment of asthma and chronic obstructive pulmonary disease (COPD) into the list of pharmaceutical benefits with the price of SEK 236.35 per piece.
04
Jun 2018

MTRC has released European reimbursement report for minimally invasive endoluminal procedures for gastro-esophageal reflux disease (GERD) in 11 EU countries

Report includes analysis for the following procedures: radiofrequency ablation, endoscopic plication and suturing, injection of bulking agents and endoscopic augmentation of the lower esophageal sphincter using hydrogel implants. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.
04
Jun 2018

MTRC has released European reimbursement report for surgical and endovascular treatment of brain aneurysm in 11 EU countries

Report includes analysis for the following procedures: surgical clipping, endovascular placement of a flow diversion device, endovascular coiling and stent-assisted coiling. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.
01
Jun 2018

MTRC released the report on innovation payment schemes in Europe

European Med Tech and IVD Reimbursement Consulting Ltd. released a report, which identifies and provides an overview of the innovative payment schemes for medical devices and in-vitro diagnostic tests in European countries. The report was supported by the grant from the Med Tech Europe. Access the full version of the report at our web-site.